Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($1.39), $0.17 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $21.85 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.